Effect of DA-8031, a novel oral compound for premature ejaculation, on male rat sexual behavior

International Journal of Urology

Volumn 21, Issue 3, 2014, Pages 325-329

  Kang, Kyung Koo ^a,b   Sung, Ji Hyun ^a   Kim, Soon Hoe ^a   Lee, Sukhyang ^b  

^a Dong A Pharmaceutical Company   (South Korea)

^b Ajou University   (South Korea)

Author keywords

Animals; DA 8031; Premature ejaculation; Sexual behavior

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; DA 8031; ISOBENZOFURAN DERIVATIVE; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COPULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; LATENT PERIOD; MALE; MATING; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PREMATURE EJACULATION; PRIORITY JOURNAL; RAT; SEXUAL BEHAVIOR;

ANIMALS; DA-8031; PREMATURE EJACULATION; SEXUAL BEHAVIOR;

ANIMALS; BENZOFURANS; HUMANS; MALE; PREMATURE EJACULATION; RATS; RATS, SPRAGUE-DAWLEY; SEXUAL BEHAVIOR;

EID: 84896711891     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12256     Document Type: Article

References (30)

1. Laumann EO, Paik A, Resen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-544.
2. Laumann EO, Nicolosi A, Glasser DB etal. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int. J. Impot. Res. 2005; 17: 39-57.
3. Hellstrom WJG, Nehra A, Shabsigh R, Sharlip ID. Premature ejaculation: the most common male sexual dysfunction. J. Sex. Med. 2006; 3 (S1): 1-3.
4. Waldinger MD, Oliver B. Utility of selective serotonin reuptake inhibitors in premature ejaculation. Curr. Opin. Investig. Drugs 2004; 5: 743-747.
5. Waldinger MD, Schweitzer DH, Olivier B. On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. J. Sex. Med. 2005; 2: 121-131.
6. McMahon CG. Dapoxetine: a new option in the medical management of premature ejaculation. Ther. Adv. Urol. 2012; 4: 233-251.
7. Waldinger MD. The neurobiological approach to premature ejaculation. J. Urol. 2002; 168: 2359-2367.
8. Waldinger MD. Premature ejaculation: definition and drug treatment. Drugs 2007; 67: 547-568.
9. Montague D, Jarow J, Broderick G etal. AUA guideline on the pharmacological management of premature ejaculation. J. Urol. 2004; 172: 290-294.
10. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 2000; 85: 11-28.
11. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J. Clin. Pharmacol. 2006; 46: 301-309.
12. Thyssen A, Sharma O, Tianmei S etal. Pharmacokinetics of dapoxetine hydrochloride in healthy Chinese, Japanese, and Caucasian men. J. Clin. Pharmacol. 2010; 50: 1450-1460.
13. Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur. Urol. 2009; 55: 957-967.
14. McCarty E, Dinsmore W. Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation. Core. Evid. 2012; 7: 1-14.
15. Kowey PR, Mudumbi RV, Aquilina JW, DiBattiste PM. Cardiovascular safety profile of dapoxetine during the premarketing evaluation. Drugs R. D. 2011; 11: 1-11.
16. Marson L, Yu G, Farber NM. The effects of oral administration of d-modafinil on male rat ejaculatory behavior. J. Sex. Med. 2010; 7: 70-78.
17. Snoeren EM, Lehtimäki J, Agmo A. Effect of dexmedetomidine on ejaculatory behavior and sexual motivation in intact male rats. Pharmacol. Biochem. Behav. 2012; 103: 345-352.
18. Jeon HJ, Kim HS, Lee CH etal. Candidate molecule for premature ejaculation, DA-8031: in vivo and in vitro characterization of DA-8031. Urology 2011; 77: e17-21.
19. Kang KK, Ahn GJ, Sung HJ, Kim SH, Kim H, Lee S. Ejaculatory responses are inhibited by a new chemical entity, DA-8031, in pre-clinical rodent models of ejaculation. Urology 2013; 81: e13-18.
20. Chahoud I, Faqi AS. An optimized approach for the assessment of sexual behavior in male rats. Reprod. Toxicol. 1998; 12: 667-671.
21. Agmo A. Male rat sexual behavior. Brain. Res. Protoc. 1997; 1: 203-209.
22. Pattij T, Olivier B, Waldinger MD. Animal models of ejaculatory behavior. Curr. Pharm. Des. 2005; 11: 4069-4077.
23. Waldinger MD, Olivier B. Animal models of premature and retarded ejaculation. World J. Urol. 2005; 23: 115-118.
24. Mos J, Mollet I, Tolboom JT, Waldinger MD, Olivier B. A comparison of the effects of different serotonin reuptake blockers on sexual behaviour of the male rat. Eur. Neuropsychopharmacol. 1999; 9: 123-135.
25. Lentz A, Gravitt K, Carson CC, Marson L. Acute and chronic dosing of Lepidium meyenii (Maca) on male rat sexual behavior. J. Sex. Med. 2007; 4: 332-339.
26. Gengo P, Marson L, Gravitt K. Actions of dapoxetine on ejaculation and sexual behavior in rats. J. Sex. Med. 2006; 3 (S3): 200.
27. de Jong TR, Pattij T, Veening JG, Waldinger MD, Cools AR, Olivier B. Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine. Psychopharmacology (Berl) 2005; 179: 509-515.
28. Waldinger MD, van De Plas A, Pattij T etal. The selective serotonin re-uptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment. Psychopharmacology (Berl) 2002; 160: 283-289.
29. Clement P, Pozzato C, Heidbreder C, Alexandre L, Giuliano F, Melotto S. Delay of ejaculation induced by SB-277011, a selective dopamine d3 receptor antagonist, in the rat. J. Sex. Med. 2009; 6: 980-988.
30. Pattij T, de Jong TR, Uitterdijk A etal. Individual differences in male rat ejaculatory behaviour: searching for models to study ejaculation disorders. Eur. J. Neurosci. 2005; 22: 724-734.